SQZ - SQZ STOCK NEWS

SQZ Biotechnologies Company (NYSE: SQZ) announced the presentation of new preclinical findings on its enhanced antigen presenting cell (eAPC) platform at the American Association for Cancer Research (AACR) Annual Meeting on April 8-13, 2022. The eAPC platform effectively delivers multiple mRNA, enhancing CD8 T cell responses against various diseases, including HPV. The FDA granted IND clearance for SQZ-eAPC-HPV, its first therapeutic candidate targeting HPV16+ solid tumors. Additionally, a Trial in Progress presentation will detail the ENVOY-001 Phase 1/2 trial of SQZ-AAC-HPV in patients with HPV-related tumors.

SQZ Biotechnologies has published significant preclinical research regarding their Cell Squeeze® platform, demonstrating its capacity to engineer immune cells (T cells, B cells, NK cells, and monocytes) for enhanced MHC-I antigen presentation, crucial for activating killer T cells in disease treatment. This research is published in the Journal of Immunology and supports the development of clinical programs. The platform aims to advance cancer vaccines and improve patient outcomes, with FDA IND clearance for enhanced APCs.

SQZ Biotechnologies has received FDA clearance for its investigational new drug application for SQZ-eAPC-HPV, enabling the initiation of the COMMANDER-001 Phase 1/2 clinical trial targeting HPV16+ solid tumors. This novel cell therapy candidate employs a unique engineering approach that combines multiple mRNAs. The trial aims to evaluate safety and tolerability while assessing clinical responses in patients. SQZ eAPCs have demonstrated promising preclinical results, highlighting their potential in oncological applications.

SQZ Biotechnologies (NYSE: SQZ) has appointed John Maraganore, Ph.D., former CEO of Alnylam Pharmaceuticals, as a strategic advisor. Maraganore, known for his extensive experience in biotech, is expected to contribute significantly to the advancement of SQZ's cell therapy programs. The company aims to leverage its proprietary Cell Squeeze technology to address multiple diseases, enhancing the accessibility of therapies. CEO Armon Sharei expressed enthusiasm about the collaboration, particularly after recent positive clinical response data.

SQZ Biotechnologies Company (NYSE: SQZ) has shared interim results from its Phase 1/2 trial for its APC therapy targeting HPV16+ tumors. A patient with checkpoint refractory head-and-neck cancer showed noteworthy clinical improvement and a complete radiographic response in the target lesion. The investigational treatment was well tolerated, with no dose-limiting toxicities observed. Notable increases in CD8 T cells and PD-L1 expression were reported. Following this progress, the trial will explore combination therapies. A conference call is scheduled for today at 8:00 a.m. ET.

SQZ Biotechnologies (NYSE: SQZ) has reported interim results from its ongoing Phase 1/2 trial of SQZ-PBMC-HPV, a cell therapy aimed at advanced HPV16+ tumors. The highest-dose cohort showed positive outcomes, including a radiographic response in a heavily treated patient and significant increases in CD8 T cell infiltration. Notably, the therapy was well tolerated without dose-limiting toxicities. The findings will be presented at the ESMO Immuno-Oncology Congress on December 9, along with plans to advance into combination therapy with checkpoint inhibitors.

SQZ Biotechnologies has joined the Roche Accelerator, which aims to enhance its strategic planning and market entry in China. This partnership underscores the company's ongoing collaboration with Roche, established in 2015, particularly in oncology programs. Armon Sharei, CEO of SQZ, highlighted the opportunity to address significant patient needs in China with their SQZ™ cell therapies. The collaboration aims to facilitate the exploration of local applications for their innovative cell therapy approach.

SQZ Biotechnologies (NYSE: SQZ) announced its participation in the 4th Annual Evercore ISI HealthCONx Conference on December 1. CEO Armon Sharei, Ph.D., will provide a corporate overview during a fireside chat scheduled from 9:15-9:35 am ET. SQZ will also conduct one-on-one meetings with attendees. Details regarding the presentation and a webcast will be accessible on the company's website for 90 days post-event. SQZ focuses on advancing cell therapies across oncology, autoimmune, and infectious disease sectors.

SQZ Biotechnologies (NYSE:SQZ) has announced its participation in the Stifel 2021 Virtual Healthcare Conference on November 17. CEO Armon Sharei, Ph.D., will provide a corporate overview and engage in one-on-one meetings. The presentation is scheduled for 10:00 am ET and will be available via webcast. Details on the webcast and corporate overview will be available on the company’s website.